Adamas Pharmaceuticals, which is developing improved formulations of existing drugs for CNS disorders, raised $48 million by offering 3.0 million shares at $16, the low end of the range of $16 to $18. Adamas Pharmaceuticals plans to list on the NASDAQ under the symbol ADMS. Adamas Pharmaceuticals initially filed confidentially on 1/31/2014. Credit Suisse and Piper Jaffray acted as joint bookrunners on the deal.
